Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077675
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2004-02-10
Brief Title:
Phase 2 Trial of TD-6424 Telavancin Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections Gram Positive cSSSI
Sponsor:
Cumberland Pharmaceuticals
Organization:
Cumberland Pharmaceuticals
Organization Data
Organization:
Cumberland Pharmaceuticals
Class:
INDUSTRY
Study ID:
I6424-202b
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cumberland Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Steven Barriere PharmD Vice President Clinical and Medical Affairs
Old Organization:
Theravance Inc